Skip to main content
Premium Trial:

Request an Annual Quote

GPC to Provide Tech to Lilly

NEW YORK, Jan. 31 - GPC Biotech of Martinsried,

Germany, will provide Eli Lilly with its proteomics-based molecular interaction screening technology, LeadCode, GPC said today.

Under the agreement, GPC will use leadcode for mechanism-of-action studies on compounds for metabolic diseases. Financial terms of the deal were not disclosed.


LeadCode is a modified yeast two-hybrid technology designed to identify the interaction of small molecules with the full complement of human proteins, according to the company said. GPC applies this technology to its internal drug-discovery program for anticancer drugs.


Click here form more information.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.